Boostrix ipv

Manufactured by GlaxoSmithKline

Sourced in Belgium

Boostrix-IPV is a vaccine manufactured by GlaxoSmithKline. It is a combination vaccine that protects against diphtheria, tetanus, pertussis (whooping cough), and polio. The vaccine is administered through an injection and is intended for use as a booster dose in individuals aged 3 years and older.

Automatically generated - may contain errors

Lab products found in correlation

Pediacel, by Sanofi (1 mentions) Infanrix ipv hib, by GlaxoSmithKline (1 mentions) Prevenar13, by Pfizer (1 mentions)

4 protocols using boostrix ipv

Longitudinal Study of Boostrix-IPV Vaccine

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

This phase IV longitudinal interventional study conducted in Finland, the Netherlands and the UK is described in detail elsewhere (10 (link)). In summary, healthy children (7-10 y), adolescents (11-15y), young adults (20-34 y), and older adults (60-70 y) received Boostrix-IPV (GlaxoSmithKline (GSK), Wavre, Belgium), a three component pertussis vaccine (Tdap3-IPV), between October 2017 and January 2019. Children were all aP primed, adolescents were either aP or wP primed, young adults were all wP primed, and older adults were either wP primed or unvaccinated. B cell assays were performed on a subset of the total study samples given the resources needed to undertake the assay (total n= 268 out of 379). Samples were selected according to a prespecified sample plan based on participant ID. For the memory B cell analyses the samples were collected before vaccination (baseline), and at day 28 and 1 year post-vaccination. Figure 1 shows the number of participants per country, per age group, and per timepoint. Their characteristics are listed in Table 1. The trial was registered at the EU Clinical Trial database (EudraCT number 2016-003678-42).

Versteegen P., Barkoff A.M., Valente Pinto M., van de Kasteele J., Knuutila A., Bibi S., de Rond L., Teräsjärvi J., Sanders K., de Zeeuw-Brouwer M.L., Luoto R., ten Hulscher H., Clutterbuck E.A., Sanders E.A., Mertsola J., Berbers G.A., He Q., Kelly D.F, & Buisman A.M. (2022). Memory B Cell Activation Induced by Pertussis Booster Vaccination in Four Age Groups of Three Countries. Frontiers in Immunology, 13, 864674.

+ Open protocol

+ Expand

Infant Vaccination Schedule in the UK

Check if the same lab product or an alternative is used in the 5 most similar protocols

In line with UK vaccine policy, vaccinated women received tetanus, diphtheria and pertussis‐containing vaccines (Tdap); Repevax^® (Sanofi Pasteur, Lyon, France; prior to July 2014) or Boostrix‐IPV^® (GlaxoSmithKline, Wavre, Belgium; after July 2014). As per routine vaccination schedules in the United Kingdom, infants received three doses of tetanus, diphtheria and pertussis‐containing vaccine at 8, 12 and 16 weeks; DtaP5‐IPV‐Hib (Pediacel^®; Sanofi Pasteur) or DtaP3‐IPV‐Hib (Infanrix‐IPV‐Hib^®; GlaxoSmithKline). All infants received two doses of 13‐valent conjugate pneumococcal polysaccharide vaccine, Prevenar13^®(Pfizer, Puurs, Belgium) at 8 and 16 weeks.

Rice T.F., Diavatopoulos D.A., Smits G.P., van Gageldonk P.G., Berbers G.A., van der Klis F.R., Vamvakas G., Donaldson B., Bouqueau M., Holder B, & Kampmann B. (2019). Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy – a prospective, observational cohort study from the United Kingdom. Clinical and Experimental Immunology, 197(1), 1-10.

+ Open protocol

+ Expand

Tdap3-IPV Vaccine Booster Immunogenicity

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Participants from the BERT study cohort [30 (link)] (N = 258) (Table 1) were included in 2017–2019 in Finland and the Netherlands, and received a booster dose of a Tdap3-IPV vaccine (Boostrix™-IPV - GlaxoSmithKline (GSK), Wavre, Belgium). Samples for this study were analyzed from pre-booster, one month after and one year after booster vaccination. All sera in this study were stored at −20 °C, and their anti-PT IgG and IgA antibodies were measured previously with a fluorescent-bead-based multiplex immunoassay at the National Institute for Public Health and the Environment, The Netherlands [30 (link), 31 (link)].

Table 1.

Study cohorts.

	Country	Age (Mean yr)	No. of study participants	No. of Female/Male	Primary vaccination*	Booster vaccinations*, age
Children	FI	9.0	37	18/19	aPv	4 years, aPv
Children	NL	8.5	36	18/18		4 years, aPv
Adolescents (aP)	FI	12.5	19	7/12	aPv	4 years, aPv
Adolescents (aP)	NL	12.4	25	17/8		4 years, aPv
Adolescents (wP)	FI	15.0	18	11/7	wPv	2 and 6 years, aPv**
Adolescents (wP)	NL	14.8	23	14/9		4 years, aPv
Young adults	FI	30.2	25	21/4	wPv	n/A
Young adults	NL	28.6	25	10/15		n/A
Older adults	FI	64.2	25	21/4	wPv	n/A
Older adults	NL	65.9	25	14/11		n/A

* Detailed vaccine compositions and schedules in Supplementary Figure 1.

** One participant was boosted by wPv at 2 years of age

Knuutila A., Versteegen P., Barkoff A.M., van Gageldonk P., Mertsola J., Berbers G, & He Q. (2022). Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups. Emerging Microbes & Infections, 11(1), 956-963.

+ Open protocol

+ Expand

Ex Vivo T-Cell Analysis Across Ages

Check if the same lab product or an alternative is used in the 5 most similar protocols

For ex vivo T-cell analysis, 73 healthy participants were included. n = 19 were 7–10 years of age (referred to as children) with an aP priming background, n = 24 were 11–15 years of age (adolescents) with either an aP or a wP priming background, n = 15 were 20–34 years of age (young adults) with a wP priming background and n = 15 were 60–70 years of age (older adults) with a unknown proportion of wP priming background or no vaccination background. The distribution of male and female participants and age is indicated in Table 1. All participants received one dose of an aP vaccine included in a combination vaccine (Tdap)-IPV (Boostrix^®-IPV, GlaxoSmithKline, Wavre, Belgium).

Lambert E.E., Corbière V., van Gaans-van den Brink J.A., Duijst M., Venkatasubramanian P.B., Simonetti E., Huynen M., Diavatopoulos D.D., Versteegen P., Berbers G.A., Mascart F, & van Els C.A. (2020). Uncovering Distinct Primary Vaccination-Dependent Profiles in Human Bordetella pertussis Specific CD4+ T-Cell Responses Using a Novel Whole Blood Assay. Vaccines, 8(2), 225.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!